RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 232 participants.

Also called NCT05134012

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 232 participants (enrolled count) (from the registry)
Sponsor
MedTrace Pharma A/S (from the registry)
Registry
  • NCT NCT05134012
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Denmark, Germany, Netherlands, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05134012. Allocation not applicable; no masking; primary purpose diagnostic. Start 2022-05-08 (actual); primary completion 2026-10-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
Intervention (Drug)
[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Lead sponsor
MedTrace Pharma A/S (class: industry)

Record details

Record id
cardio:ct-nct05134012
Content hash
d2f06649c38000b7ae87700a0422ff7964c84138684f62d40e5ab38c7fb1f6dd